# US 2022/0031709 A1 · Inhibition of microsomal prostaglandin e2 (pge2) synthase-1 (mpges-1)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031709 A1
- Document ID: US20220031709A1
- Status: Published application
- Kind: A1
- Application number: 17/393,210
- Filed: 2021-08-03
- Published: 2022-02-03
- Earliest claimed: 2020-08-03
- Applicants: University of Kentucky Research Foundation
- Inventors: Chang-Guo Zhan; Fang Zheng; Shuo Zhou; Ziyuan Zhou
- Web page: https://patentgrep.com/patent/US20220031709A1

## CPC

- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/14: for RNA viruses
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed methods of inhibiting microsomal prostaglandin E2 (PGE2) synthase-1 (mPGES-1) make use of ceftriaxone, aztreonam, cefotetan, pharmaceutically-acceptable salts thereof, and combinations thereof.

## Claims

### Claim 1

A method of inhibiting expression or activity of prostaglandin E2 (PGE2) in a cell, comprising contacting the cell with or introducing into the cell an effective amount of an mPGES-1 inhibitor, selected from the group consisting of ceftriaxone, aztreonam, cefotetan, pharmaceutically-acceptable salts thereof, and combinations thereof, wherein the contacting or introducing results in inhibition of expression or activity of PGE2 in the cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein the inhibitor is ceftriaxone or a pharmaceutically-acceptable salt thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the inhibitor is aztreonam or a pharmaceutically-acceptable salt thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the inhibitor is cefotetan or a pharmaceutically-acceptable salt thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the inhibitor is provided in a pharmaceutical composition further comprising a pharmaceutically-acceptable carrier.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cell is in a subject.

### Claim 7

A method of treating coronavirus in a subject, comprising administering to the subject an effective amount of an mPGES-1 inhibitor, selected from the group consisting of ceftriaxone, aztreonam, cefotetan, pharmaceutically-acceptable salts thereof, and combinations thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein the coronavirus is SARS-CoV-2.

### Claim 9 (depends on 7)

The method of claim 7, and further comprising identifying the subject as having been exposed to the coronavirus, having tested positive for the coronavirus, and/or displaying one or more symptoms associated with the coronavirus.

### Claim 10 (depends on 7)

The method of claim 7, wherein the mPGES-1 inhibitor is administered without any additional active agents.

### Claim 11 (depends on 7)

The method of claim 7, and further comprising administering an anti-viral agent.

### Claim 12 (depends on 11)

The method of claim 11, wherein the anti-viral agent is selected from the group consisting of remdesivir, chloroquine, hydroxychloroquine, oseltamivir, favipiravir, umifenovir, and galidesivir.

### Claim 13

A method of reducing inflammation in a subject, comprising administering to the subject an effective amount of an mPGES-1 inhibitor, selected from the group consisting of ceftriaxone, aztreonam, cefotetan, pharmaceutically-acceptable salts thereof, and combinations thereof.

### Claim 14 (depends on 13)

The method of claim 13, and further comprising identifying the subject as having edema.

### Claim 15 (depends on 13)

The method of claim 13, and further comprising identifying the subject as having stroke, sepsis, pneumonia, airway inflammation, heart failure, typhoid fever, or vascular inflammation.

### Claim 16 (depends on 15)

The method of claim 15, wherein the subject has vascular inflammation that is an abdominal aortic aneurysm (AAA).

### Claim 17

A method of reducing pain in a subject, comprising administering to the subject an effective amount of an mPGES-1 inhibitor, selected from the group consisting of ceftriaxone, aztreonam, cefotetan, pharmaceutically-acceptable salts thereof, and combinations thereof.

### Claim 18 (depends on 17)

The method of claim 17, and further comprising identifying the subject as having pain.

### Claim 19 (depends on 17)

The method of claim 17, and further comprising identifying the subject as having hyperalgesia.

### Claim 20 (depends on 17)

The method of claim 17, and further comprising identifying the subject has having arthritis pain.